Rhythm Pharmaceuticals Reports 54% Revenue Growth in Q3 2025, Faces Increased Losses

Rhythm Pharmaceuticals, Inc. reported a significant increase in financial performance for the third quarter of 2025, with net product revenue reaching $51.3 million, a 54% increase from $33.3 million in the same period last year. For the nine months ended September 30, 2025, total revenues amounted to $132.5 million, up 50% from $88.3 million in the prior year. The company attributed this growth primarily to increased sales volume of its lead product, IMCIVREE® (setmelanotide), which is designed to treat rare neuroendocrine diseases associated with obesity. However, the company also faced a net loss of $52.9 million for the quarter, compared to a loss of $43.6 million in the same period of 2024.

In terms of operational changes, Rhythm Pharmaceuticals experienced a notable increase in costs, with total expenses rising to $104.0 million for the third quarter, up 35% from $77.1 million a year earlier. This increase was driven by higher selling, general, and administrative expenses, which rose by 48% to $52.4 million, as well as a 21% increase in research and development costs, totaling $46.0 million. The company’s accumulated deficit as of September 30, 2025, stood at $1.3 billion, reflecting ongoing investments in product development and commercialization efforts.

The company has also made strategic advancements, including the acceptance of a supplemental New Drug Application (sNDA) by the U.S. FDA for setmelanotide, seeking approval for the treatment of conditions associated with hypothalamic obesity. The FDA granted Priority Review status, with a Prescription Drug User Fee Act (PDUFA) goal date set for December 20, 2025. Additionally, Rhythm Pharmaceuticals has expanded its market access, achieving sales of IMCIVREE in over 25 countries outside the U.S. and continuing to collaborate with authorities for further access.

As of September 30, 2025, Rhythm Pharmaceuticals reported cash and cash equivalents of approximately $52.1 million, alongside short-term investments totaling $363.9 million, providing a total liquidity position of $416.1 million. The company anticipates that these resources will be sufficient to fund operations for at least the next 24 months. However, management has indicated that ongoing operating losses are expected to continue, necessitating future funding through equity or debt financing to support research and development activities and commercialization efforts. The company remains focused on advancing its clinical programs and expanding its commercial infrastructure in both the U.S. and international markets.